Free Trial

Geron (GERN) Competitors

Geron logo
$1.42 +0.03 (+1.79%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$1.42 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GERN vs. ALKS, LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, and NVAX

Should you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

Geron vs. Its Competitors

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Geron presently has a consensus price target of $5.06, indicating a potential upside of 255.26%. Alkermes has a consensus price target of $40.00, indicating a potential upside of 39.13%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.78
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 7.4% of Geron shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$76.99M11.79-$174.57M-$0.21-6.79
Alkermes$1.56B3.04$367.07M$2.0913.76

Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-119.54% -47.86% -26.78%
Alkermes 23.30%27.52%17.98%

In the previous week, Alkermes had 10 more articles in the media than Geron. MarketBeat recorded 10 mentions for Alkermes and 0 mentions for Geron. Alkermes' average media sentiment score of 1.10 beat Geron's score of 0.00 indicating that Alkermes is being referred to more favorably in the news media.

Company Overall Sentiment
Geron Neutral
Alkermes Positive

Geron has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Summary

Alkermes beats Geron on 12 of the 16 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$910.79M$2.92B$5.56B$9.05B
Dividend YieldN/A2.44%5.24%3.99%
P/E Ratio-6.7921.5627.6520.23
Price / Sales11.79283.26419.56119.26
Price / CashN/A41.7026.2128.59
Price / Book3.107.538.035.65
Net Income-$174.57M-$55.14M$3.18B$249.15M
7 Day Performance-4.36%4.61%2.93%3.28%
1 Month Performance-10.94%0.90%1.72%3.95%
1 Year Performance-68.54%5.40%34.39%20.98%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
2.8427 of 5 stars
$1.43
+1.8%
$5.06
+255.3%
-68.5%$910.79M$76.99M-6.7970
ALKS
Alkermes
4.9344 of 5 stars
$28.60
-0.7%
$40.00
+39.9%
+18.4%$4.72B$1.56B13.681,800Positive News
Analyst Revision
LGND
Ligand Pharmaceuticals
4.8114 of 5 stars
$113.68
-0.4%
$146.14
+28.6%
+35.6%$2.19B$167.13M-15.9780News Coverage
BCRX
BioCryst Pharmaceuticals
4.4641 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+37.2%$1.87B$450.71M-34.46530Analyst Forecast
Analyst Revision
FOLD
Amicus Therapeutics
3.7015 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-38.6%$1.76B$528.29M-63.66480
CLDX
Celldex Therapeutics
3.066 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-38.1%$1.35B$7.02M-7.54150Positive News
INVA
Innoviva
3.8918 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+17.4%$1.26B$358.71M-19.89100Positive News
DVAX
Dynavax Technologies
4.3933 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-8.6%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5262 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-29.7%$1.14B$297.60M37.40400
OPK
OPKO Health
4.443 of 5 stars
$1.32
flat
$2.75
+108.3%
+6.7%$1.05B$713.10M-18.852,997Positive News
NVAX
Novavax
4.4897 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-42.9%$1.02B$682.16M2.381,990

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners